AstraZeneca has just wrapped its second immuno-oncology deal in as many days, turning to Heptares to in-license an experimental drug that promises to improve the punch of its checkpoint inhibitor durvalumab (MEDI4736). The pharma giant will hand over a $10 million upfront payment for the collaboration, with up to $500 million in development and commercialization milestones--on top of a royalty stream from any approved products.
AstraZeneca's big MedImmune subsidiary has a new partner for its closely-watched PD-L1 checkpoint inhibitor durvalumab (MEDI4736). Little Mirati Therapeutics, which is run by some high-profile cancer R&D execs, has struck a deal to pair the therapy with its HDAC inhibitor, mocetinostat, against non-small cell lung cancer.
GlobeImmune, reeling from a costly clinical failure, secured a commitment from long-time partner Celgene to collaborate on a new cancer immunotherapy.
Pennsylvania drugmaker Zynerba Pharmaceuticals is making its way to Wall Street with some cannabis-derived treatments for central nervous system disorders, raising $42 million in an IPO.
A California judge has stepped between two top research institutions fighting over a vast Alzheimer's disease R&D program with ties to Big Pharma, ordering the study's new managers to hand it back for the time being.
The mystery of Ron Evans' new biotech startup has been solved. Armed with $36 million in cash from A-list venture investors and backed by a pro team recruited from Rich Heyman's Aragon/Seragon starring cancer drug startups, the prominent Salk investigator and his old buddy Heyman are coming out of stealth mode today with a new company called Metacrine.
Intec Pharma has raised $30 million (€28 million) in an IPO on Nasdaq. The haul is down on the most recent target--and represents a discount on its share price in Tel Aviv--but still gives Intec some money to throw at a Phase III trial of its Parkinson's disease candidate.
Baxalta execs didn't like the idea of a $30 billion all-share Shire buyout when they heard it the first time on July 10--and they didn't warm to it at all when Shire decided to go public with the offer Tuesday morning.
Galapagos has presented a surprise-free update on the trial of its AbbVie-partnered rheumatoid arthritis drug, filgotinib. The data led observers to cut the odds of AbbVie of taking up its $200 million (€182 million) buy-in option--or even making a bid to acquire Galapagos outright--and led to the company's stock hitting an all-time high on Euronext Amsterdam.
After a hectic period in which every biopharma seemed to be seeking to relocate its way to a lower tax rate, the furor over who pays what and where has died down a little in recent months. But the number crunchers are still working away in the background--and in the case of Cortendo they are on the cusp of engineering a move to Ireland.
Hedge fund Kerrisdale Capital has orchestrated an attack on Bavarian Nordic, the centerpiece of which is a 52-page report that argues the valuation of the Danish drugmaker is based on misplaced faith in the likelihood of its cancer vaccine succeeding in Phase III.
Israeli pharma giant Teva Pharmaceutical is investing in Cambridge, MA's Immuneering, taking up a stake in the genomics upstart and tapping its expertise to help guide internal drug development.
California biotech Aimmune Therapeutics has dialed up its IPO ambitions, angling for as much as $153 million this week as it pushes forward with a midstage therapy for peanut allergy.
BioMarin's executive team zeroed in on its late-stage R&D efforts for rare diseases on Monday after outlining a surge in Q2 revenue and a beat on analysts' expected losses for the quarter.
Regeneron, toasting the approval of its latest treatment and riding the success of its last one, is investing more and more into R&D, lining up a stable of new therapies with blockbuster ambitions.
Whether looking at Phase III success, drug launches or product sales, biopharma is hitting its stride in R&D, according to new analysis from Thomson Reuters. And, as the industry evolves its approach to research and regulators speed up the review process, the latest upswing could be a sign of better days ahead for drug developers.
After getting stiff-armed by the newly independent management at Baxter's biotech spinoff Baxalta, Shire is going public with its offer to acquire the company for $30.6 billion in shares. The deal marks Shire CEO Flemming Ornskov's play to make a landmark acquisition that can vault the company into the big leagues, after being left at the altar last year by AbbVie.
Baxalta, recently spun out from Baxter, is charging toward its first drug approvals under a new identity, publishing positive results for a bleeding treatment awaiting word from the FDA.
Bristol-Myers Squibb has signed on Northwestern University to partner on some early-stage immunotherapy trials.
Sorrento Therapeutics, among many companies in the orbit of billionaire entrepreneur Patrick Soon-Shiong, is looking to take a spot in the growing market for knockoffs of the world's top-selling biotech medicines.